Appendix 1—table 2. Pharmacokinetic exposure from the individual analysis and pharmacodynamic parameters.
| Pharmacokinetics | |||
|---|---|---|---|
| Sofosbuvir | GS-331007 | Daclatasvir | |
| AUClast (h×ng/mL) | 1,140 (598-2,150) | 3,430 (2,200-4,720) | 9,770 (5,080-16,200) |
| Pharmacodynamics | |||
| AUC (days ×IU/mL) | 252,000 (19,200-1,370,000) | ||
| t1/2 (days) | 2.25 (0.986–5.22) | ||
| %ReductionEnrolment-Day1 | 99.9 (99.0–100) | ||
| %ReductionEnrolment-Day7 | 100 (100–100) |
Data is presented as median (5th –95th percentile). AUClast is the total exposure to the last time point (8 hours for SOF and 24 hours for GS-331007 and DCV). AUC14 is the area under the viral load-time curve from enrolment (day 0) to day 14, t1/2 is the terminal viral half-life (estimated using at least three measurements), %ReductionEnrolment-Day1 is the reduction in viral load from enrolment to day 1, %ReductionEnrolment-Day7 is the reduction in viral load from enrolment to day 7.
The half-life could not be determined for one participant due to only one sample above the lower limit of quantification.